HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. (September 2006)

• Record Type: Journal Article
• Authors: Alfirevic, Ana; Jorgensen, Andrea L; Williamson, Paula R; Chadwick, David W; Park, B Kevin; Pirmohamed, Munir
• Is Part Of: Pharmacogenomics. Volume 7:Number 6(2006)
• Page Start: 813
• Page End: 818
• Publication Date: 2006-09
• Subjects: adverse drug reactions -- carbamazepine -- epilepsy -- HLA-B -- hypersensitivity -- pharmacogenetics; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/14622416.7.6.813
• Languages: English
• ISSNs: 1462-2416

Abstract

Background: A strong pharmacogenetic association has been reported in Chinese patients between human leukocyte antigen ( HLA )- B*1502 and carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS).Methods: We have genotyped the HLA-B alleles in 56 Caucasian patients with varying severities of CBZ hypersensitivity and 43 controls on CBZ without adverse effects.Results: None of our patients (including two with blistering skin rashes) were positive for the HLA-B*1502 allele. HLA-B*0702 allele may protect against severe CBZ hypersensitivity but warrants further study. Of secondary interest, the correlation between HLA-B*0801 and HLA-DR3, DQ2 and TNF -308 alleles (on the ancestral haplotype 8.1) is consistent with our previous findings.Conclusion: HLA-B*1502 does not seem to be a marker for all forms of CBZ-induced hypersensitivity in a Caucasian population.